Agência para o Investimento e Comércio Externo de Portugal


Diverse panel of novel target binders from FairJourney Biologics and IONTAS will be used to uncover functional antibodies to advance autoimmune and inflammatory disease research.

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases.


More here